News

Rituxan’s Efficacy May Be Linked to It Blocking How B-cells and Certain T-cells Interact, Study Says

Blocking the interaction between immune B-cells and CD8-positive T-cells may be what makes Rituxan (rituximab) an effective treatment for ANCA-associated vasculitis (AAV), a study reports. Findings of the study, “B cell depletion therapy dampens CD8+ T cell response in ANCA‐associated vasculitis,” were published in Arthritis & Rheumatology.

Many ANCA-associated Vasculitis Patients Develop Hypersensitivity to Azathioprine, Study Shows

Nearly one in 10 ANCA-associated vasculitis (AAV) patients receiving azathioprine as a maintenance treatment for their condition develop hypersensitivity to the therapy, which manifests as whole body inflammation and skin eruptions, increasing the risk of relapse. Researchers should be aware of this complication, which is more common than previously thought, to…

Cyclophosphamide and Rituxan May Safely Treat AAV Patients During Pregnancy, Study Finds

Standard therapies used to ANCA-associated vasculitis (AAV), like cyclophosphamide or Rituxan (rituximab), appear to be of benefit in patients who are pregnant, a literature review suggests. The study, “Successful treatment outcomes in pregnant patients with ANCA‐associated vasculitides: A systematic review of literature,” was published in the International Journal…